Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity
- PMID: 24763910
- DOI: 10.1007/s00213-014-3573-7
Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity
Abstract
Rationale: Opioid antagonism reduces the consumption of palatable foods in humans but the neural substrates implicated in these effects are less well understood.
Objectives: The aim of the present study was to examine the effects of the opioid antagonist, naltrexone, on neural response to rewarding and aversive sight and taste stimuli.
Methods: We used functional magnetic resonance imaging (fMRI) to examine the neural responses to the sight and taste of pleasant (chocolate) and aversive (mouldy strawberry) stimuli in 20 healthy volunteers who received a single oral dose of naltrexone (50 mg) and placebo in a double-blind, repeated-measures cross-over, design.
Results: Relative to placebo, naltrexone decreased reward activation to chocolate in the dorsal anterior cingulate cortex and caudate, and increased aversive-related activation to unpleasant strawberry in the amygdala and anterior insula.
Conclusions: These findings suggest that modulation of key brain areas involved in reward processing, cognitive control and habit formation such as the dorsal anterior cingulate cortex (dACC) and caudate might underlie reduction in food intake with opioid antagonism. Furthermore we show for the first time that naltrexone can increase activations related to aversive food stimuli. These results support further investigation of opioid treatments in obesity.
Similar articles
-
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.Int J Neuropsychopharmacol. 2014 Dec 25;18(6):pyu094. doi: 10.1093/ijnp/pyu094. Int J Neuropsychopharmacol. 2014. PMID: 25542687 Free PMC article. Clinical Trial.
-
The D2 antagonist sulpiride modulates the neural processing of both rewarding and aversive stimuli in healthy volunteers.Psychopharmacology (Berl). 2011 Sep;217(2):271-8. doi: 10.1007/s00213-011-2278-4. Epub 2011 Apr 15. Psychopharmacology (Berl). 2011. PMID: 21494790 Free PMC article. Clinical Trial.
-
Effects of pramipexole on the processing of rewarding and aversive taste stimuli.Psychopharmacology (Berl). 2013 Jul;228(2):283-90. doi: 10.1007/s00213-013-3033-9. Epub 2013 Mar 14. Psychopharmacology (Berl). 2013. PMID: 23483198 Clinical Trial.
-
Enhanced neural response to anticipation, effort and consummation of reward and aversion during bupropion treatment.Psychol Med. 2016 Aug;46(11):2263-74. doi: 10.1017/S003329171600088X. Epub 2016 May 18. Psychol Med. 2016. PMID: 27188979 Clinical Trial.
-
Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.Pharmacol Res. 2014 Jun;84:1-11. doi: 10.1016/j.phrs.2014.04.004. Epub 2014 Apr 19. Pharmacol Res. 2014. PMID: 24754973 Review.
Cited by
-
Tobacco withdrawal increases junk food intake: The role of the endogenous opioid system.Drug Alcohol Depend. 2021 Aug 1;225:108819. doi: 10.1016/j.drugalcdep.2021.108819. Epub 2021 Jun 18. Drug Alcohol Depend. 2021. PMID: 34182373 Free PMC article.
-
Naltrexone alters the processing of social and emotional stimuli in healthy adults.Soc Neurosci. 2016 Dec;11(6):579-91. doi: 10.1080/17470919.2015.1136355. Epub 2016 Jan 22. Soc Neurosci. 2016. PMID: 26710657 Free PMC article.
-
Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.J Psychiatry Neurosci. 2018 Jul;43(4):254-261. doi: 10.1503/jpn.170036. J Psychiatry Neurosci. 2018. PMID: 29947607 Free PMC article. Clinical Trial.
-
Neural Correlates of Anti-appetite Medications: An fMRI Meta-analysis.Curr Neuropharmacol. 2021;19(11):2049-2056. doi: 10.2174/1570159X19666210914142227. Curr Neuropharmacol. 2021. PMID: 34521327 Free PMC article.
-
Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research.Neuropsychopharmacology. 2019 Jan;44(2):259-273. doi: 10.1038/s41386-018-0232-4. Epub 2018 Oct 3. Neuropsychopharmacology. 2019. PMID: 30283002 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical